Catalyst Pharmaceuticals CCO Sells 74% of Holdings for ~$256,200
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Source: Fool
- Executive Sell-off: Catalyst Pharmaceuticals' Chief Commercial Officer Jeffrey Del Carmen exercised and sold 10,983 shares on November 26, 2025, for approximately $256,200, significantly reducing his direct holdings to 3,962 shares, indicating a cautious outlook on the company's future stock performance.
- Ownership Change: The 10,983 shares sold represented about 73.49% of Del Carmen's direct equity holdings, which materially decreases his stake and may affect market perceptions regarding executive confidence in the company.
- Historical Transaction Comparison: Since August 2024, Del Carmen has completed three sales, and while the current transaction size is smaller, the high percentage sold raises investor concerns, especially against the backdrop of the company's recent strong performance.
- Company Performance Context: Catalyst reported third-quarter revenues of $148.4 million, up 17.4% year-over-year, and raised its full-year 2025 revenue guidance, suggesting that despite the insider selling, the company's ongoing profitable growth momentum remains encouraging.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CPRX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CPRX
Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 34.00 USD with a low forecast of 33.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.200
Low
33.00
Averages
34.00
High
35.00
Current: 24.200
Low
33.00
Averages
34.00
High
35.00
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halozyme and Catalyst Report Double-Digit Revenue Growth, Strong Outlook
- Halozyme Financial Performance: Halozyme's Q3 revenue increased by 22% year-over-year to $354 million, with earnings per share (EPS) soaring 36% to $1.43, demonstrating its strong market position in drug delivery systems.
- Catalyst Growth Potential: Catalyst achieved a remarkable 249% revenue growth leading up to 2024, with Q3 revenue rising 24% year-over-year to $436.3 million and EPS climbing 45.9% to $1.27, reflecting strong demand in rare disease treatments.
- Competitive Advantage: Both companies maintain low debt levels, with Halozyme reducing its long-term debt from $1.5 billion to $800 million, while Catalyst has no debt, providing them with greater flexibility for acquisitions and R&D investments.
- Optimistic Industry Outlook: The biotech sector rebounded in 2025, with the SPDR S&P Biotech ETF rising 27%, indicating a resurgence in market demand for innovative drugs, while both Halozyme and Catalyst are valued below the sector average, suggesting significant future growth potential.
Continue Reading
Biotech Recovery: Halozyme and Catalyst Stocks Surge Amid Strong Growth
- Biotech Recovery: In 2025, the SPDR S&P Biotech ETF surged 27%, nearly doubling the S&P 500's 16% gain, indicating a robust recovery in the biotech sector, supported by lower interest rates facilitating debt financing.
- Halozyme's Strong Growth: Halozyme Therapeutics saw its stock rise over 25% in the past year, with Q3 revenue increasing 22% year-over-year to $354 million and EPS jumping 36% to $1.43, showcasing its competitive edge in drug delivery systems.
- Catalyst's Profitability: Catalyst Pharmaceuticals reported a staggering 249% revenue growth from 2021 to 2024, with a 24% year-over-year increase in revenue to $436.3 million and a 45.9% rise in EPS to $1.27 this year, reflecting strong market demand in rare disease treatments.
- Optimistic Future Outlook: Halozyme forecasts annual revenue of $1.3 billion to $1.375 billion for 2026, representing 28% to 35% growth, while Catalyst anticipates revenue of $565 million to $585 million, nearly a 17% increase, indicating promising growth potential for both companies.
Continue Reading